Unknown Cancer NIHR-supported project Lungs & Breathing

A Phase I-III, Multicenter Study Evaluating The Efficacy And Safety Of Multiple Therapies In Cohorts Of Patients With Resectable Stage I-III Non-small Cell Lung Cancer, Selected According To Biomarker Status

Funder NIHR (part of DHSC)
Recipient organisation NIHR Wellcome Trust Manchester Clinical Research Facility
NIHR support Recorded as supported by this research centre
Period Jan 2025 — Ongoing

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Yvonne Summers (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A phase I-II multicentre study evaluating the efficacy and safety of multiple therapies in cohorts of patients selected according to biomarker status with locally advanced, unresectable stage III NSCLC La Roche Ltd Dr Laura Cove-Smith
Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer (NSCLC)(National Lung Matrix Trial)
A Phase III, Double-Blinded, Multicenter, Randomized study evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolimzumab or Placebo in combination with Platinum-based Chemotherapy in Patients with Resectable Stage II, IIIA, or select IIIB Non-Small Cell Lung Cancer
A Multi-drug, genetic marker-directed, non comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer.
A Phase III, Double-blind, Randomised, Placebo-Controlled,International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.